PresseBox
Press release BoxID: 269286 (Roche Diagnostics Deutschland GmbH)
  • Roche Diagnostics Deutschland GmbH
  • Sandhofer Str. 116
  • 68305 Mannheim
  • http://www.roche.de/
  • Contact person
  • Burkhard Ziebolz
  • +49 (8856) 60-4830

High-Resolution Digital Imaging with Cedex HiRes from Roche Innovatis

(PresseBox) (Penzberg, ) Roche Innovatis has launched Cedex HiRes, the newest generation of image-based Cedex Cell Counter and Analyzer systems for automated cell culture analysis. Cedex HiRes measures cell density, viability, aggregation rate, cell morphology, and cell debris using the Trypan Blue exclusion method, with high-resolution digital image recognition. The exceptional image quality allows deeper insights into even the subtlest changes in a cell culture, such as monitoring baculovirus transfections for protein production via measurement of cell diameter changes. Designed to work in a production environment while strictly adhering to quality guidelines, Cedex HiRes uses software with extensive capabilities for data management and control to ensure compliance with all current Good Manufacturing Practices (cGMP) regulations.

New instrument features account for reduced operator time and increased analytical accuracy. Up to 20 individual samples of 300 µl each are handled by the multi-sampler. Cell staining and mixing tasks are fully automated, as are focus adjustments. Cedex HiRes produces images with pixel resolution of 0.8 µm, enabling the distinction of objects with a distance of less than 2 µm to each other. Detectable cell diameter range is 2 µm - 40 µm, and object diameter range of 1 µm - 90 µm. Digital image recognition allows for permanent storage of acquired data.

Developed in close collaboration with customers, the Cedex HiRes features Cedex 2 Software that simplifies the visualization, transfer and storage of the most elaborate data sets for true automation in cGMP regulated environments. Through its Systems Suitability Test (SST), Roche Innovatis provides consumables and maintenance protocols that allow users to routinely verify and document system quality and ensure measurement performance.

Roche Innovatis is a world leading technology provider focused on developing, manufacturing, and supporting automated cell culture analysis. In research, in development, and in production, Roche Innovatis provides the biomedical research community with systems and services that enable the development of effective vaccines, therapies and treatments. Systems include Cedex, the leading cell analysis systems in the biotechnology and pharmaceutical industry; CuBiAn, membrane-free, automated biochemistry analyzers for cell cultures; Cellavista, image based systems for multi-mode capture of cellular images; and, CASY, a compact system for cell counting and viability analysis. Services include implementation of analytical hardware, software and interfaces for seamless integration with existing process control enterprises. Roche Innovatis enables fully automated systems to exist in compliance with regulatory standards in a validated environment.

All trademarks used or mentioned in this release are protected by law.

CEDEX, CUBIAN, and CELLAVISTA are trademarks of Roche.

Roche Diagnostics Deutschland GmbH

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients.

In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.